Information Provided By: 
Fly News Breaks for September 7, 2016
BMRN
Sep 7, 2016 | 06:36 EDT
JPMorgan analyst Cory Kasimov says he continues to expect BioMarin's Brineura to be approved and launched in the first half of 2017 after the FDA delayed the PDUFA by three months. The key takeaway from last night's announcement, the analyst contends, is that the data with an additional eight month of follow-up is "even stronger." Kasimov is "somewhat surprised" by the extended action date as the drug was also granted priority review and Breakthrough designation. He reiterates an Overweight rating on BioMarin Pharmaceuticals.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
